Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Muvalaplin (LY3473329) 是一种具有口服活性的脂蛋白 (a) Lp (a) 抑制剂,可阻断 apo(a)-apo B100 相互作用来抑制 Lp(a) 的形成。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 1,330 | 现货 | ||
5 mg | ¥ 3,380 | 现货 | ||
10 mg | ¥ 4,960 | 现货 | ||
25 mg | ¥ 7,790 | 现货 | ||
50 mg | ¥ 9,870 | 现货 | ||
100 mg | ¥ 13,900 | 现货 |
产品描述 | Muvalaplin (LY3473329) is an orally active lipoprotein (a) Lp(a) reagent that inhibits Lp(a) formation by blocking apo(a)-apo B100 interactions. |
体内活性 | The single ascending dose treatment evaluated the effect of a single dose of Muvalaplin ranging from 1 mg to 800 mg or placebo taken by healthy participants with any Lp(a) level. The multiple ascending dose treatment evaluated the effect of taking daily doses of Muvalaplin (30 mg to 800 mg) or placebo for 14 days in patients with Lp(a) levels of 30 mg/dL or higher. Oral doses of 30 mg to 800 mg for 14 days resulted in increasing Muvalaplin plasma concentrations and half-life ranging from 70 to 414 hours. Muvalaplin lowered Lp(a) plasma levels within 24 hours after the first dose, with further Lp(a) reduction on repeated dosing. Maximum placebo-adjusted Lp(a) reduction was 63% to 65%, resulting in Lp(a) plasma levels less than 50 mg/dL in 93% of participants, with similar effects at daily doses of 100 mg or more. No clinically significant changes in plasminogen levels or activity were observed. Conclusion: Muvalaplin, a selective small molecule inhibitor of Lp(a) formation, was not associated with tolerability concerns and lowered Lp(a) levels up to 65% following daily administration for 14 days.[2] |
别名 | LY3473329 |
分子量 | 710.9 |
分子式 | C42H54N4O6 |
CAS No. | 2565656-70-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 10 mg/mL (14.07 mM), when pH is adjusted to 6. Sonication is recommended.
H2O: <0.1 mg/mL
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 1.4067 mL | 7.0333 mL | 14.0667 mL | 35.1667 mL |
5 mM | 0.2813 mL | 1.4067 mL | 2.8133 mL | 7.0333 mL | |
10 mM | 0.1407 mL | 0.7033 mL | 1.4067 mL | 3.5167 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Muvalaplin 2565656-70-2 Others LY-3473329 LY 3473329 LY3473329 Inhibitor inhibitor inhibit